ASM supports proposed Accelerating Biomedical Research Act
ASM President Timothy Donohue said the bill, which was introduced by Sen. Tom Harkin (D-Iowa), would represent a step in the right direction by providing support for critically needed innovative biomedical research and reestablishing the NIH's purchasing power, according to an ASM press release.
"The ASM is very concerned about the future of biomedical research in the United States," Donohue said. "NIH support for basic research is critical to health and security, job creation and growing the US economy. The success rate for NIH research grant applicants has fallen to historic lows below 17 percent. The effects of sequestration included delayed research projects, loss of technical staff, halts to approved or ongoing clinical trials, and waning innovation."
Donohue said that decreased funding for biomedical research slows U.S. scientific progress at a time when other nations are increasing their investment in biomedical research. He thanked Harkin for his continued support of the NIH.
According to the American Society for Pharmacology and Experimental Therapeutics (ASPET), the proposed legislation represents an effort to fix the funding restraints imposed on the NIH by the Budget Control Act of 2011. ASPET said the bill would allow for more sustainable growth than the NIH has seen in more than a decade.